Amyloid deposits not associated with depression in the elderly
Depression in elderly people can include symptoms such as memory loss, making it hard to distinguish from the early stages of Alzheimer’s disease and other types of dementia. A signature of Alzheimer’s is accumulation of a protein called amyloid beta (Aβ) in the brain, which can be detected with brain-imaging technology.
Researchers had suspected that Aβ deposits might also underlie the cognitive decline seen in older people with depression, however a new study from researchers at the University of California, San Francisco (UCSF) has found that abnormal Aβ deposits were actually found in fewer older adults with major depression compared to non-depressed control subjects. The study appears in Biological Psychiatry, published by Elsevier.
John Krystal, editor of Biological Psychiatry, said of the work: “In the elderly, depression can sometimes be difficult to tease apart from dementia. This important study finds that late-life depression was not associated with increased deposition of beta-amyloid in the brain, a hallmark of Alzheimer’s disease.This insight is important, because tests—like the PET scans that enable detection of deposited amyloid—may someday play a role in helping doctors to make this distinction.”
The study included 119 older adults with major depression and 119 non-depressed participants with an average age of 71. All of the depressed participants were enrolled in the Alzheimer’s Disease Neuroimaging Initiative’s Depression (ADNI-D) Project, a large research collaboration between multiple research agencies and universities. None of the participants in the current study had been diagnosed with dementia. The researchers collected blood and DNA samples from the subjects, and they used positron emission tomography (PET) to detect Aβ deposits in their brains.
“Surprisingly, we did not observe evidence of increased amyloid deposition in theparticipants with major depression,” said Principal Investigator and lead author Scott Mackin, Ph.D., and professor of psychiatry at the UCSF Weill Institute for Neurosciences, San Francisco, CA, U.S.. “Instead, we saw decreased amyloid deposition when we compared the groups in several different ways.”
Significant amyloid protein deposits were detected in just 19 percent of participants with depression compared with 31 percent of control subjects.
As expected, subjects with depression performed worse on cognitive and memory tests than non-depressed subjects. In addition, participants with brain amyloid deposits performed worse on the memory tests, but this was true regardless of whether they had depression or not. “Depression had a strong impact on memory performance independent of amyloid deposition,” Dr. Mackin said.
Together, the findings indicate that depression is a risk factor for cognitive decline, but that it probably works through some mechanism other than amyloid deposition.
The presence of amyloid deposits did not depend on a patient’s history of depression or use of anti-depressant treatments, which, Dr. Mackin said, “would suggest that depressed mood, or depression treatments, are also likely not protective against amyloid deposition.”
According to the authors, the findings generated many new questions that will need to be investigated.